On June 26, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced a public offering of 30,769,230 shares of its Class A common stock at $6.50 per share. The offering, which is expected to close on June 28, 2024, subject to customary closing conditions, could raise approximately $200 million, or up to $230 million if the underwriters exercise their option to purchase additional shares. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as the representatives of the underwriters for this offering. The company has also entered into lock-up agreements with its executive officers, directors, and certain related entities, restricting the sale of securities for a 45-day period. The offering is made under Recursion's effective registration statement on Form S-3 and related prospectus filed with the SEC. The company aims to use the proceeds for development activities and other corporate purposes, leveraging its Recursion Operating System to industrialize drug discovery.

On June 26, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced a public offering of 30,769,230 shares of its Class A common stock at $6.50 per share. The offering, which is expected to close on June 28, 2024, subject to customary closing conditions, could raise approximately $200 million, or up to $230 million if the underwriters exercise their option to purchase additional shares. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as the representatives of the underwriters for this offering. The company has also entered into lock-up agreements with its executive officers, directors, and certain related entities, restricting the sale of securities for a 45-day period. The offering is made under Recursion's effective registration statement on Form S-3 and related prospectus filed with the SEC. The company aims to use the proceeds for development activities and other corporate purposes, leveraging its Recursion Operating System to industrialize drug discovery.